XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.24.3

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2024
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information |
|  | For the Three Months Ended September 30, 2024
|  | Medical Office and Life Science Portfolio |  | SHOP |  | Non-Segment |  | Consolidated
Revenues: |  |  |  |  |  |  |  |
Rental income |  | $ | 52,901 |  |  | $ | — |  |  | $ | 8,734 |  |  | $ | 61,635 |
Residents fees and services |  | — |  |  | 312,005 |  |  | — |  |  | 312,005 |
Total revenues |  | 52,901 |  |  | 312,005 |  |  | 8,734 |  |  | 373,640 |
Expenses: |  |  |  |  |  |  |  |
Property operating expenses |  | 25,074 |  |  | 284,572 |  |  | 51 |  |  | 309,697 |
Depreciation and amortization |  | 18,773 |  |  | 47,343 |  |  | 2,843 |  |  | 68,959 |
General and administrative |  | — |  |  | — |  |  | 13,933 |  |  | 13,933 |
Acquisition and certain other transaction related costs |  | — |  |  | — |  |  | 331 |  |  | 331 |
Impairment of assets |  | 23,031 |  |  | — |  |  | — |  |  | 23,031 |
Total expenses |  | 66,878 |  |  | 331,915 |  |  | 17,158 |  |  | 415,951 |
Gain on sale of properties |  | 111 |  |  | — |  |  | — |  |  | 111 |
Interest and other income |  | — |  |  | — |  |  | 2,575 |  |  | 2,575 |
Interest expense |  | (2,319) |  |  | (54) |  |  | (57,070) |  |  | (59,443) |
Loss before income tax expense and equity in net earnings (losses) of investees |  | (16,185) |  |  | (19,964) |  |  | (62,919) |  |  | (99,068) |
Income tax expense |  | — |  |  | — |  |  | (148) |  |  | (148) |
Equity in net earnings (losses) of investees |  | 1,707 |  |  | — |  |  | (1,180) |  |  | 527 |
Net loss |  | $ | (14,478) |  |  | $ | (19,964) |  |  | $ | (64,247) |  |  | $ | (98,689) |
|  | For the Nine Months Ended September 30, 2024
|  | Medical Office and Life Science Portfolio |  | SHOP |  | Non-Segment |  | Consolidated
Revenues: |  |  |  |  |  |  |  |
Rental income |  | $ | 161,605 |  |  | $ | — |  |  | $ | 25,550 |  |  | $ | 187,155 |
Residents fees and services |  | — |  |  | 928,653 |  |  | — |  |  | 928,653 |
Total revenues |  | 161,605 |  |  | 928,653 |  |  | 25,550 |  |  | 1,115,808 |
Expenses: |  |  |  |  |  |  |  |
Property operating expenses |  | 73,253 |  |  | 847,526 |  |  | 587 |  |  | 921,366 |
Depreciation and amortization |  | 58,488 |  |  | 141,176 |  |  | 7,785 |  |  | 207,449 |
General and administrative |  | — |  |  | — |  |  | 27,763 |  |  | 27,763 |
Acquisition and certain other transaction related costs |  | — |  |  | — |  |  | 2,243 |  |  | 2,243 |
Impairment of assets |  | 41,718 |  |  | — |  |  | — |  |  | 41,718 |
Total expenses |  | 173,459 |  |  | 988,702 |  |  | 38,378 |  |  | 1,200,539 |
Loss on sale of properties |  | (18,976) |  |  | — |  |  | — |  |  | (18,976) |
Interest and other income |  | — |  |  | — |  |  | 7,215 |  |  | 7,215 |
Interest expense |  | (3,435) |  |  | (183) |  |  | (172,103) |  |  | (175,721) |
Loss on modification or early extinguishment of debt |  | — |  |  | — |  |  | (209) |  |  | (209) |
Loss before income tax expense and equity in net (losses) earnings of investees |  | (34,265) |  |  | (60,232) |  |  | (177,925) |  |  | (272,422) |
Income tax expense |  | — |  |  | — |  |  | (505) |  |  | (505) |
Equity in net (losses) earnings of investees |  | (18,173) |  |  | — |  |  | 8,291 |  |  | (9,882) |
Net loss |  | $ | (52,438) |  |  | $ | (60,232) |  |  | $ | (170,139) |  |  | $ | (282,809) |
|  | As of September 30, 2024
|  | Medical Office and Life Science Portfolio |  | SHOP |  | Non-Segment |  | Consolidated
Total assets |  | $ | 1,726,082 |  |  | $ | 3,111,775 |  |  | $ | 447,339 |  |  | $ | 5,285,196 |
|  | For the Three Months Ended September 30, 2023
|  | Medical Office and Life Science Portfolio |  | SHOP |  | Non-Segment |  | Consolidated
Revenues: |  |  |  |  |  |  |  |
Rental income |  | $ | 55,058 |  |  | $ | — |  |  | $ | 8,332 |  |  | $ | 63,390 |
Residents fees and services |  | — |  |  | 293,134 |  |  | — |  |  | 293,134 |
Total revenues |  | 55,058 |  |  | 293,134 |  |  | 8,332 |  |  | 356,524 |
Expenses: |  |  |  |  |  |  |  |
Property operating expenses |  | 25,784 |  |  | 272,445 |  |  | 203 |  |  | 298,432 |
Depreciation and amortization |  | 20,175 |  |  | 44,587 |  |  | 2,474 |  |  | 67,236 |
General and administrative |  | — |  |  | — |  |  | 6,954 |  |  | 6,954 |
Acquisition and certain other transaction related costs |  | — |  |  | — |  |  | 3,676 |  |  | 3,676 |
Impairment of assets |  | 427 |  |  | 729 |  |  | — |  |  | 1,156 |
Total expenses |  | 46,386 |  |  | 317,761 |  |  | 13,307 |  |  | 377,454 |
Interest and other income |  | — |  |  | 115 |  |  | 3,128 |  |  | 3,243 |
Interest expense |  | (119) |  |  | (79) |  |  | (47,560) |  |  | (47,758) |
Income (loss) before income tax expense and equity in net losses of investees |  | 8,553 |  |  | (24,591) |  |  | (49,407) |  |  | (65,445) |
Income tax expense |  | — |  |  | — |  |  | (189) |  |  | (189) |
Equity in net losses of investees |  | (145) |  |  | — |  |  | — |  |  | (145) |
Net income (loss) |  | $ | 8,408 |  |  | $ | (24,591) |  |  | $ | (49,596) |  |  | $ | (65,779) |
|  | For the Nine Months Ended September 30, 2023
|  | Medical Office and Life Science Portfolio |  | SHOP |  | Non-Segment |  | Consolidated
Revenues: |  |  |  |  |  |  |  |
Rental income |  | $ | 165,448 |  |  | $ | — |  |  | $ | 25,753 |  |  | $ | 191,201 |
Residents fees and services |  | — |  |  | 857,572 |  |  | — |  |  | 857,572 |
Total revenues |  | 165,448 |  |  | 857,572 |  |  | 25,753 |  |  | 1,048,773 |
Expenses: |  |  |  |  |  |  |  |
Property operating expenses |  | 73,237 |  |  | 796,733 |  |  | 770 |  |  | 870,740 |
Depreciation and amortization |  | 63,065 |  |  | 129,891 |  |  | 7,474 |  |  | 200,430 |
General and administrative |  | — |  |  | — |  |  | 20,111 |  |  | 20,111 |
Acquisition and certain other transaction related costs |  | — |  |  | — |  |  | 9,812 |  |  | 9,812 |
Impairment of assets |  | 14,034 |  |  | 4,346 |  |  | — |  |  | 18,380 |
Total expenses |  | 150,336 |  |  | 930,970 |  |  | 38,167 |  |  | 1,119,473 |
Gain on sale of properties |  | — |  |  | 1,233 |  |  | — |  |  | 1,233 |
Gains on equity securities, net |  | — |  |  | — |  |  | 8,126 |  |  | 8,126 |
Interest and other income |  | — |  |  | 1,581 |  |  | 10,991 |  |  | 12,572 |
Interest expense |  | (344) |  |  | (502) |  |  | (142,076) |  |  | (142,922) |
Loss on modification or early extinguishment of debt |  | — |  |  | — |  |  | (1,075) |  |  | (1,075) |
Income (loss) before income tax expense and equity in net earnings of investees |  | 14,768 |  |  | (71,086) |  |  | (136,448) |  |  | (192,766) |
Income tax expense |  | — |  |  | — |  |  | (379) |  |  | (379) |
Equity in net earnings of investees |  | 2,137 |  |  | — |  |  | — |  |  | 2,137 |
Net income (loss) |  | $ | 16,905 |  |  | $ | (71,086) |  |  | $ | (136,827) |  |  | $ | (191,008) |
| As of December 31, 2023
| Medical Office and Life Science Portfolio |  | SHOP |  | Non-Segment |  | Consolidated
Total assets | $ | 1,866,422 |  |  | $ | 3,134,978 |  |  | $ | 444,736 |  |  | $ | 5,446,136 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration